Skip to main content

COVID-19 Topic Center

Chronic Lymphocytic Leukemia Expert Insights

Population Health Learning Network
Based on a median follow-up of four years, John Allen, MD, assistant professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine, New York-Presbyterian Hospital, explains how first-line ibrutinib-based treatment resulted in sustained efficacy with high…
Population Health Learning Network
William G. Wierda, MD, PhD, professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discusses the results of the Phase II CAPTIVATE study, and highlights how the use of Ibrutinib plus Venetoclax confers high rates of peripheral blood and bone marrow undetectable…
Back to Top